As a note of caution, several other potential drugs are reportedly cardioprotective in anthracycline cardiotoxicity models, such as thrombopoietin [25], erythropoietin [53], melatonin [36], CB1 cannabinoid receptor antagonists [54], granulocyte colony-stimulating factor [55], and ErbB2 [56], so that proof of concept in other forms of cardiomyopathy will be required to advance the concept of an α1A agonist as a drug to treat HF. Here, THPO is linked to cardiomyopathy.